Mizuho lowered the firm’s price target on Herbalife (HLF) to $7 from $9 and keeps a Neutral rating on the shares. The firm says 2025 opens with U.S. Food valuations near 20-year lows vs. the S&P 500 and weaker expectations for EPS given soft volumes and limited pricing power. In addition, continued uncertainty about demand related to GLP-1s and new regulatory concerns should limit investors’ appetites to own the space in the near term. Mizuho believes that most models remain capable of normalized positive mid- to high-single-digit EPS, but views 2025 as an investment year including rising potential for pricing adjustments across categories where consumption remains weak following inflation.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.